Product Data Sheet: Phospho-Jun-(S63)

Cat. No:	MAB-94227
Conjugate:	Unconjugated
Size:	100 ug
Clone:	54B3
Concentration:	1mg/ml
Host:	Rb
Isotype:	IgG
Reactivity:	Hu
Applications:	Western Blot: 1:1000 Immunofluorescence 1:50 – 1:200
Molecular Weight:	48 kDa
Purification:	Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues around Ser63 of human c-Jun.
Background:	c-Jun is a member of the Jun Family containing c-Jun, JunB and JunD, and is a component of the transcription factor AP-1 (activator protein-1). AP-1 is composed of dimers of Fos, Jun and ATF family members and binds to and activates transcription at TRE/AP-1 elements (reviewed in 1). Extracellular signals including growth factors, chemokines and stress activate AP-1-dependent tran-scription. The transcriptional activity of c-Jun is regulated by phosphorylation at Ser63 and Ser73 through SAPK/JNK (reviewed in 2). Knock-out studies in mice have shown that c-Jun is essential for embryogenesis (3), and subsequent studies have demonstrated roles for c-Jun in various tissues and developmental processes including axon regeneration (4), liver regeneration (5) and T cell development (6). AP-1 regulated genes exert diverse biological functions including cell proliferation, differentiation, and apoptosis, as well as transformation, invasion and metastasis, depending on cell type and context (7-9). Other target genes regulate survival as well as hypoxia and angiogenesis (8,10). c-Jun has emerged as a promising therapeutic target for cancer, vascular remodeling, acute inflammation, as well as rheumatoid arthritis (11,12).Phospho-c-Jun (Ser63) (54B3) Rabbit mAb detects endogenous levels of c-Jun only when phosphorylated at serine 63.
Form:	liquid
Buffer:	PBS with 0.02% sodium azide,50% glycerol,pH7.3.
Storage:	Store at -20℃. Avoid freeze / thaw cycles.

References

(1) Jochum, W. et al. (2001) Oncogene 20, 2401-12. (2) Davis, R.J. (2000) Cell 103, 239-52. (3) Hilberg, F. et al. (1993) Nature 365, 179-81. (4) Raivich, G. et al. (2004) Neuron 43, 57-67. (5) Behrens, A. et al. (2002) EMBO J 21, 1782-90. (6) Riera-Sans, L. and Behrens, A. (2007) J Immunol 178, 5690-700. (7) Leppä, S. and Bohmann, D. (1999) Oncogene 18, 6158-62. (8) Shaulian, E. and Karin, M. (2002) Nat Cell Biol 4, E131-6. (9) Weiss, C. and Bohmann, D. (2004) Cell Cycle 3, 111-3. (10) Karamouzis, M.V. et al. (2007) Mol Cancer Res 5, 109-20. (11) Kim, S. and Iwao, H. (2003) J Pharmacol Sci 91, 177-81. (12) Dass, C.R. and Choong, P.F. (2008) Pharmazie 63, 411-4.

For Research use only
IMMUNOLOGICAL SCIENCES